Report cover image

Cold Agglutinin Disease (CAD)

Publisher Reach Market Research
Published Jul 01, 2022
Length 33 Pages
SKU # RMR19136490

Description

MarketVue®: Cold Agglutinin Disease

The MarketVue®: Cold Agglutinin Disease market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.

Topics covered in this report:
• Disease overview: Review the disease pathophysiology and potential druggable targets
• Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
• Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
• Unmet needs: Identify opportunities to address treatment or disease management gaps
• Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
• Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing

Methodology:
Research for the MarketVue®: Cold Agglutinin Disease report is supported by 9 qualitative interviews with key opinion leaders, a quantitative survey with 25 U.S. physicians and secondary research.

Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)

Key companies mentioned:
• Sanofi/Genzyme
• Swedish Orphan Biovitrum AB (SOBI)
• Apellis Pharmaceuticals
• Novartis

Key drugs mentioned:
• Rituximab (Rituxan)
• Bendamustine
• Fludarabine (Fludara)
• Sutimlimab (Enjaymo)
• Corticosteroids
• Venetoclax (Venclexta)
• Bortezomib (Velcade)
• Ibrutinib (Imbruvica)
• Iptacopan (Fabhalta)
• Pegcetacoplan (Empaveli)
• SAR445088

Please note: the online download version of this report is for a global site license.

Table of Contents

33 Pages
1. DISEASE OVERVIEW
A rare, cold-activated, autoimmune bone marrow disorder characterized by hemolytic anemia
Figure 1.1. Classical complement pathway in CAD
CAD is characterized by anemia-related and cold-associated symptoms
Table 1.1. Clinical presentation of CAD
Figure 1.2. Hematologist-reported segmentation of their CAD patient population
2. EPIDEMIOLOGY & PATIENT POPULATIONS
Disease definition
Figure 2.1 – Diagnosed prevalent cases of CAD by region
Table 2.1 – Diagnosed prevalent and drug-treated patients in the U.S. and EU5
3. DIAGNOSIS AND CURRENT TREATMENT
Diagnosis overview
Figure 3.1. Diagnostic pathway for CAD patients
B-cell and complement-directed therapy are the current standards of care
Overview
Figure 3.2. Treatment goals for CAD
Figure 3.3. Current treatment patient share
Treatment flow for CAD
Figure 3.4. Treatment algorithm for CAD
Rituximab-based regimens are the most widely used treatments for CAD in US and EU
Figure 3.5. Hematologist rating (n=25) of current therapy effectiveness in CAD
Figure 3.6. Hematologist-reported percentage of CAD patients who are refractory to rituximab
There is room for improvement over existing treatments
Hematologists’ opinions on current treatments
Severity of anemia and dosing are critical drivers of treatment choice between rituximab and Enjaymo
Enjaymo is the first and only USFDA-approved drug for primary CAD
Enjaymo is viewed favorably in the US and EU, with a few reservations
Figure 3.7. Enjaymo’s advantages observed in clinical practice
Figure 3.8. Percentage of hematologists who rated Enjaymo as “extremely favorable” for its attributes
Figure 3.9. Percentage of hematologists familiar with Enjaymo
Hematologists’ perception of Enjaymo
Key treatment dynamics that shape disease management and drug use in CAD
Table 3.1 Must-know CAD treatment dynamics
Figure 3.10. Hematologist-reported percentage of patients with unsatisfactory outcomes with current CAD treatments
Complement pathway inhibition is the future of CAD therapy
Figure 3.11. Important dynamics of CAD market evolution
4. UNMET NEED
Overview
Figure 4.1 – Top unmet needs in CAD
Figure 4.2 – Physician-reported unmet needs in CAD
Important unmet needs in treating CAD remain
Figure 4.3 – Three unmet needs in CAD despite the addition of sutimlimab as a treatment option
Non-clinical barriers to care - physician perspective
Figure 4.4 – Percent of hematologists who see this as a barrier to receiving drug therapy
5. PIPELINE ANALYSIS
Overview
Figure 5.1. Number of emerging CAD therapies whose clinical trial primary end points target top unmet needs
Pipeline for CAD is limited
Table 5.1. Comparison of ongoing trials of complement-mediated therapies in CAD
Emerging therapies are complement inhibitors
Figure 5.2. Percentage of hematologists who rated the following emerging therapies as “promising”
Figure 5.3. Percentage of hematologists who rated emerging target or approach as “promising”
6. VALUE & ACCESS
Overview
Table 6.1 – Current therapy pricing
Table 6.2 – Typical commercial payer coverage of Rituxan and Enjaymo (e.g., United Healthcare, Aetna, BlueCross BlueShield, Cigna)
Key market access dynamics that will continue to shape treatment use
Figure 6.1 – CAD patients by insurance type
Thoughts from european physicians surrounding current and future access to CAD therapies
Drug Analogue: Soliris, Ultomiris, and Empaveli in PNH
Overview
Commercial payer requirement of drug analogues
Table 6.3. Summary of commercial insurance requirements for Empaveli, Ultomiris, and Soliris
Drug Analogue: Soliris in PNH
Overview
Figure 6.2. Annual cost (WAC) of Soliris (000s), 2007 – 2021
Figure 6.3. Key market access pillars for Soliris in PNH
Drug Analogue: Empaveli and Ultomiris in PNH
Overview
Figure 6.4. Strategies used by Ultomiris and Empaveli to compete with Soliris
Thoughts from European physicians surrounding current and future access to CAD therapies
7. METHODOLOGY
Primary market research approach
Epidemiology methodology

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us